Future aspects of immunotherapy and gene therapy in neuroblastoma

Aktas S.

JOURNAL OF BUON, cilt.14, 2009 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14
  • Basım Tarihi: 2009
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: gene therapy, immunotherapy, neuroblastoma, STEM-CELL TRANSPLANTATION, HIGH-RISK NEUROBLASTOMA, CANCER-IMMUNOTHERAPY, DENDRITIC CELLS, MURINE NEUROBLASTOMA, TUMOR VACCINE, IMMUNITY, MODULATION, BEDSIDE, BENCH
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Immunotherapy against cancer aims (it stimulating the immune system or building an immune response against targeted tumor-associated antigens (TAAs). It was proposed theoretically as a potential therapy for cancer over a century ago but it became popular in the past two decades. Gene therapy represents a promising approach for reversing the neoplastic phenotype or driving tumor cells to self-destruction. Although survival rates Of neuroblastoma (NB) with biologically favorable disease are greater than 90%, outcomes of patients with high risk disease are less than 40%. Stage 4 metastatic NB cases over 18 months of age are often incurable with multimodality) chemotherapy regimens. In this article, translation of immuno-gene therapy strategies into clinical trials for NB are reviewed. Future aspects of immuno-gene therapy are discussed.